Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000935836-25-000710
Filing Date
2025-11-18
Accepted
2025-11-18 17:57:13
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 17452
2 ex9920251112.htm EX-99 5236
3 dsgn_trans.htm EX-99.2 4507
  Complete submission text file 0000935836-25-000710.txt   28949
Mailing Address 1 LETTERMAN DRIVE BLDG C, SUITE C3-350 SAN FRANCISCO CA 94129
Business Address 1 LETTERMAN DRIVE BLDG C, SUITE C3-350 SAN FRANCISCO CA 94129 4158014660
Logos Global Management LP (Filed by) CIK: 0001792126 (see all company filings)

EIN.: 833997742 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 6005 HIDDEN VALLEY ROAD SUITE 110 CARLSBAD CA 92011
Business Address 6005 HIDDEN VALLEY ROAD SUITE 110 CARLSBAD CA 92011 858-293-4900
Design Therapeutics, Inc. (Subject) CIK: 0001807120 (see all company filings)

EIN.: 823929248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92462 | Film No.: 251496145
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)